Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irina A Favorskaya

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Viruses|August 28, 2025
Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in MiceDaria V Voronina, Irina V Vavilova, Olga V Zubkova, et al.
Viruses|November 11, 2022
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus InfectionDaria V Voronina, Dmitry V Shcheblyakov, Irina A Favorskaya, et al.
International Journal of Biological Macromolecules|November 22, 2024
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domainNikolai N Sluchanko, Irina V Sokolova, Irina A Favorskaya, et al.
Biochemistry. Biokhimiia|September 1, 2024
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding DomainNikolai N Sluchanko, Dmitry V Shcheblyakov, Larisa A Varfolomeeva, et al.
Frontiers in Immunology|April 17, 2023
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19Ilias B Esmagambetov, Ekaterina I Ryabova, Artem A Derkaev, et al.
Frontiers in Immunology|April 8, 2026
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variantsAnastasia I Korobkova, Irina A Favorskaya, Inna V Shuliakova, et al.
Frontiers in Immunology|June 22, 2026
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primatesEkaterina I Ryabova, Artem A Derkaev, Ilias B Esmagambetov, et al.
Frontiers in Immunology|March 14, 2022
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of ConcernIrina A Favorskaya, Dmitry V Shcheblyakov, Ilias B Esmagambetov, et al.
International Journal of Biological Macromolecules|June 21, 2025
Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activityDmitry V Shcheblyakov, Irina A Favorskaya, Inna V Dolzhikova, et al.
Vaccines|December 24, 2025
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus ChallengeTatiana A Ozharovskaia, Olga V Zubkova, Elizaveta V Korobova, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Viruses|August 28, 2025
Single-Dose Intranasal or Intramuscular Administration of Simian Adenovirus-Based H1N1 Vaccine Induces a Robust Humoral Response and Complete Protection in MiceDaria V Voronina, Irina V Vavilova, Olga V Zubkova, et al.
Viruses|November 11, 2022
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus InfectionDaria V Voronina, Dmitry V Shcheblyakov, Irina A Favorskaya, et al.
International Journal of Biological Macromolecules|November 22, 2024
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domainNikolai N Sluchanko, Irina V Sokolova, Irina A Favorskaya, et al.
Biochemistry. Biokhimiia|September 1, 2024
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding DomainNikolai N Sluchanko, Dmitry V Shcheblyakov, Larisa A Varfolomeeva, et al.
Frontiers in Immunology|April 17, 2023
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19Ilias B Esmagambetov, Ekaterina I Ryabova, Artem A Derkaev, et al.
Frontiers in Immunology|April 8, 2026
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variantsAnastasia I Korobkova, Irina A Favorskaya, Inna V Shuliakova, et al.
Frontiers in Immunology|June 22, 2026
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primatesEkaterina I Ryabova, Artem A Derkaev, Ilias B Esmagambetov, et al.
Frontiers in Immunology|March 14, 2022
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of ConcernIrina A Favorskaya, Dmitry V Shcheblyakov, Ilias B Esmagambetov, et al.
International Journal of Biological Macromolecules|June 21, 2025
Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activityDmitry V Shcheblyakov, Irina A Favorskaya, Inna V Dolzhikova, et al.
Vaccines|December 24, 2025
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus ChallengeTatiana A Ozharovskaia, Olga V Zubkova, Elizaveta V Korobova, et al.
Pageof 2